Click here for slides on this topic


Overweight

An above-normal body weight; having a body mass index (BMI) of 25 to 29.9 kg/m2.
The following content matched the glossary term: Overweight

AHA ADA prevention of CVD in T2D - Metabolic Bariatric Surgery for Weight Management

Top

Summary of recommendations for bariatric surgery for obese patients from the AHA ADA cardiovascular disease (CVD) prevention in type 2 diabetes guidelines.

AHA ADA prevention of CVD in T2D - Pharmacologic Therapy for Weight Management

Top

Summary of pharmacologic therapy options for weight loss from the AHA ADA cardiovascular disease (CVD) prevention in type 2 diabetes guidelines.

AACE 2015 guidelines Obesity Management

Top

Summary of the obesity treatment algorithm, including pharmacologic therapy and bariatric surgery, from the 2015 AACE diabetes guidelines 

AACE 2015 guidelines Diabetes Diagnosis

Top

Summary of recommendations for screening and diagnosing type 2 diabetes from the 2015 AACE guidelines. 

Endocrine Society obesity clinical practice guideline

Top

Summary of guidelines for managing obesity with pharmacologic therapy from the Endocrine Society.

NDEI.org Expert Commentary Phentermine-topiramate for weight loss in type 2 diabetes Silvio Inzucchi

Top

EXPERT COMMENTARY Expert blog post from Silvio E. Inzucchi, MD: "Weight loss remains a great challenge for our patients, especially those with diabetes."

Weight-loss therapy in type 2 diabetes effects of phentermine and topiramate extended-release

Top

Exclusive! Expert diabetes blog post from Silvio Inzucchi, MD. Garvey WT, Ryan DH, Bohannan NJV, et al. Weight loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014;37(12):3309-3316.

Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes

Top

Exclusive! Expert diabetes blog post from Silvio E. Inzucchi, MD. Espeland MA, Glick HA, Bertoni A, et al; for the Look AHEAD Research Group. Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes: The Action for Health in Diabetes. Diabetes Care. 2014;37:2548-2566.

Managing the Patient With Type 2 Diabetes and Heart Failure

Top

.style1 FONT FAMILY Arial, Helvetica, sans serif COLOR #004685

Endocrine Society Guideline on Diabetes and Pregnancy - Glycemic Targets & Glucose Management

Top

Diabetes Management Guidelines Endocrine Society Guideline on Diabetes and Pregnancy   Source Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 98(11) 4227 4249. Available here.Refer to

1 2 3 4 5 6 7 8 9 10 Next 

Slide Library Results

Search Results for: Overweight Slides Found: 164
Beneficial Lifestyle Changes: Physical Activity Improves Glycemic Control
Opportunities and Challenges for Care Extended Family Roles
Cancer Mortality According to Body Mass Index
Assessing Risk: Is Measurement of Waist Circumference Necessary?
Physician Attitudes Toward Obese Patients
Medical Nutrition Therapy: Additional Considerations
Effect of Weight Watchers® on Weight Loss
FTC Guidelines for Commercial Weight Loss Programs
Adiponectin and CRP Levels in Healthy Obese Women
Successful Weight Loss Maintenance: National Weight Control Registry
Successful Weight Loss Maintenance: National Weight Control Registry (cont’d)
Effect of Phentermine on Weight Loss in Obese Patients With Type 1 or Type 2 Diabetes
Beneficial Lifestyle Changes: Physical Activity Improves Glycemic Control
Effect of 4 Diets on Weight Loss and Cardiac Risk Factors
Prevalence of IFG in Nondiabetic US Adolescents (Aged 12–19 Yrs)
INTERHEART: Waist-to-Hip Ratio Is a Better Predictor for MI Than BMI
Prevalence of Overweight/Obesity Among US Adults (NHANES 2003-2004)
Prevalence of Overweight/Obesity Among US Adults by Sex/Ethnicity (NHANES 2003-2004)
Prevalence of Overweight* Among US Children and Adolescents
Framingham Offspring Study: 8-Year Incidence of Type 2 Diabetes by BMI
Cardiovascular Mortality in Patients With Coronary Artery Disease by BMI
Finnish Diabetes Prevention Study: Sustained Benefit of Lifestyle Intervention
Overweight Trends in Children and Adolescents
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Any Diabetes Endpoint
UKPDS: Intensive Metformin vs Conventional Therapy: Diabetes Endpoints
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Myocardial Infarction
UKPDS: Intensive Metformin vs Conventional Therapy: Myocardial Infarction
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Death From Any Cause
UKPDS: Intensive Metformin vs Conventional Therapy: Death From Any Cause
High-Monounsaturated Fat Diet Vs High-Carbohydrate Diet: Effects on A1C, Glucose, Body Weight
Prevalence of IFG, IGT, and Prediabetes by Cardiometabolic Risk Factors
Prevalence of IFG, IGT, and Prediabetes According to a Combination of Central Obesity and Hyperinsulinemia
LOADD: Nutritional Intervention for Persistent, Treated Hyperglycemia
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Design
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Results
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Additional Results
CONQUER: Design
CONQUER: Randomization and Endpoints
CONQUER: Subject Profile
CONQUER Co-Primary Outcome: Change in Body Weight
CONQUER Co-Primary Outcome: Proportion of Subjects Achieving ≥5% Weight Loss
CONQUER: Secondary Outcomes and Adverse Events
BLOOM-DM: Design
BLOOM-DM: Primary and Secondary Endpoints
BLOOM-DM: Subject Profile
BLOOM-DM Co-Primary Endpoint: Proportion of Subjects Achieving ≥5% Reduction in Baseline Body Weight
BLOOM-DM Co-Primary Endpoint: Change in Body Weight
BLOOM-DM Co-Primary Endpoint: Proportion of Subjects Achieving ≥10% Reduction in Baseline Body Weight
BLOOM-DM: Secondary Endpoints
BLOOM-DM: Adverse Events
SEQUEL: Design Extension of CONQUER Study
SEQUEL: Primary and Secondary Outcomes
SEQUEL Co-Primary Outcome: Change in Body Weight
SEQUEL Co-Primary Outcome: Proportion of Subjects Achieving ≥5% Weight Loss
SEQUEL: Secondary Outcomes and Adverse Events
Obesity Trends Among US Adults
NHANES: Obesity Prevalence and BMI Trends Among US Adults
NHANES: Age-Adjusted Combined Obesity and Overweight Prevalence Among US Adults Aged ≥20 Years, 2009-2010
NHANES: Age-Adjusted Combined Obesity and Overweight Prevalence Among US Men Aged ≥20 Years by Race/Ethnicity, 2009-2010
NHANES: Age-Adjusted Combined Obesity and Overweight Prevalence Among US Women Aged ≥20 Years by Race/Ethnicity, 2009-2010
NHANES: Age-Adjusted Obesity and Overweight Prevalence Stratified by BMI and Race/Ethnicity Among US Adults Aged ≥20 Years, 2009-2010
Obesity and Overweight Statistics
Health Consequences of Obesity
NHANES: Obesity Prevalence and BMI Trends Among US Children and Adolescents
Aggregate Years of Life Lost Due to Obesity, 2008
Pooled Analysis: Mortality Among Normal and Overweight/Obese Subjects with Diabetes
Pooled Analysis: Mortality Rates Among Normal and Overweight/Obese Subjects with Diabetes
Pooled Analysis: Mortality Higher in Normal-Weight Subjects with Diabetes
Pooled Analysis: Mortality Among Normal and Overweight/Obese Subjects with Diabetes
Look AHEAD: 1-Year Interim Results
Look AHEAD at 1 Year: Interventions
Look AHEAD at 1 Year: Change in Body Weight
Look AHEAD at 1 Year: Change in Fitness Levels
Look AHEAD at 1 Year: Additional Results
Look AHEAD: Design
Look AHEAD: 4-Year Data Analysis
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Key Facts on Prevalence, Epidemiology
Guidelines for Children and Adolescents With Type 2 Diabetes: Weight Loss, Diet (1 of 2)
Type 2 Diabetes Remission in Look AHEAD
PREDIMED: Mediterranean Diet for Primary Prevention of CVD
Look AHEAD: No Reduction in CV Events with Lifestyle Changes
Look AHEAD: No Reduction in Secondary CV Outcomes with Lifestyle Changes
Look AHEAD: Greater Weight Reduction with Lifestyle Changes
Look AHEAD: Lifestyle Changes Improve Glycemic Control, CV Risk Factors
Look AHEAD: Primary Outcome, Participant Characteristics
ADA Nutrition Guidelines: Energy Balance
AHA/ACC/TOS Obesity Guidelines: Weight Loss Outcomes in Overweight or Obese Adults
AHA/ACC/TOS Obesity Guidelines: CVD and All-Cause Mortality With High BMI
AHA/ACC/TOS Obesity Guidelines: Dietary Strategies for Weight Loss
AHA/ACC/TOS Obesity Guidelines: Recommended Diets for Weight Loss in Overweight and Obese Adults
AHA/ACC/TOS Obesity Guidelines: High-Intensity, Onsite Lifestyle Intervention
AHA/ACC/TOS Obesity Guidelines: Comprehensive Lifestyle Interventions
AHA/ACC/TOS Obesity Guidelines: Bariatric Surgery Outcomes
AHA/ACC/TOS Obesity Guidelines: Predictors of Weight Loss With Bariatric Surgery
AHA/ACC/TOS Obesity Guidelines: Bariatric Surgery Complications
AHA/ACC/TOS Obesity Guidelines: Complications Seen With Bariatric Surgery
AHA/ACC/TOS Obesity Guidelines: Identifying Candidates for Weight Loss
AHA/ACC/TOS Obesity Guidelines: Counseling on Benefits of Weight Loss
AHA/ACC/TOS Obesity Guidelines: Prescribing Diets for Weight Loss
AHA/ACC/TOS Obesity Guidelines: Lifestyle Intervention for Weight Loss in Adults
AHA/ACC/TOS Obesity Guidelines: Lifestyle Intervention for Weight Maintenance in Adults
AHA/ACC/TOS: Candidates for Bariatric Surgery
AHA/ACC/TOS Obesity Guidelines: Assessing BMI & Determining Readiness for Lifestyle Changes
AHA/ACC/TOS Obesity Guidelines: Treatment Algorithm for Overweight & Obese Adults Committed to Weight Loss
AHA/ACC/TOS Obesity Guidelines: Treatment Algorithm for Achieving & Maintaining Weight Loss
AHA/ACC/TOS Obesity Guidelines: Efficacy of Weight Loss Interventions
STAMPEDE: A1C Less Than or Equal to 6.0 Percent at 3 Yrs With Bariatric Surgery Vs Medical Therapy
SEQUEL Subanalysis: Percent Weight Loss from Baseline at Wk 108 Primary Endpoint
SEQUEL Subanalysis: Annualized Incidence of Type 2 Diabetes at Wk 108
SEQUEL Subanalysis: Reduction of Type 2 Diabetes Incidence Related to Greater Weight Loss
SEQUEL Subanalysis: Design
Diabetes Pregnancy Guidelines Preconception Endocrine Society | NDEI
Look AHEAD Impact of Intensive Lifestyle Health Costs Diabetes Slide | NDEI
Look AHEAD Intensive Lifestyle Reduces Healthcare Use Diabetes Slide | NDEI
Look AHEAD Intensive Lifestyle Reduces Health Costs Diabetes Slide | NDEI
Look AHEAD Intensive Lifestyle Reduces 10-Yr Diabetes Health Costs | NDEI
Look AHEAD Diabetes Costs Differ By CVD History Slide | NDEI
Look AHEAD Healthcare Utilization & Cost Analysis Diabetes Slide | NDEI
Lorcaserin Phentermine Overweight Obesity Adverse Events | NDEI
Lorcaserin + Phentermine Weight Loss Overweight Obese | NDEI
Lorcaserin + Phentermine Overweight Obese Weight Loss | NDEI
SCALE Obesity & Prediabetes Study Liraglutide Overweight Obesity | NDEI
SCALE-Diabetes Liraglutide Weight Loss QoL Obesity/Overweight | NDEI
BLOOM-DM Lorcaserin Glycemic Effect Type 2 Diabetes | NDEI
US Adults Who May Be Candidates for Obesity Therapy | NDEI
Efficacy of Phentermine + Topiramate for Weight Loss With BMI ≥35
Phentermine + Topiramate for Weight Loss in Type 2 Diabetes | NDEI PPT
Greater Weight Loss With Phentermine + Topiramate Obesity Type 2 Diabetes | NDEI
Phentermine + Topiramate A1C Targets Obese Subjects With Type 2 Diabetes | NDEI
Phentermine + Topiramate Decreases Need for Antidiabetic Treatments CONQUER | NDEI
Phentermine + Topiramate Safety Obesity Type 2 Diabetes | NDEI PPT
Phentermine Plus Topiramate Weight Loss Obesity Type 2 Diabetes | NDEI
EMPA-REG Blood Pressure Lowering With Empagliflozin Type 2 Diabetes Hypertension | NDEI
EMPA-REG Blood Pressure Reductions With Empagliflozin SGLT2 | NDEI PPT
EMPA-REG A1C & Weight Loss Empagliflozin SGLT2 Type 2 Diabetes | NDEI
EMPA-REG Safety of Empagliflozin in Type 2 Diabetes & Hypertension SGLT2 | NDEI
EMPA-REG BP: A1C, BP, & Weight Reduction With Empagliflozin in Type 2 Diabetes & Hypertension Clinical Significance for HCPs
ADA Type 1 Diabetes Guidelines Diagnosis Clues Slide | NDEI
Noninsulin Therapies ADA Type 1 Diabetes Guidelines | NDEI Slides
Hypoglycemia Management ADA Type 1 Diabetes Guidelines | NDEI
Management of Obesity Endocrine Society Guidelines 2015 PPT | NDEI
Treatment Strategies for Long-Term Weight Loss ENDO Obesity Guidelines | NDEI
Match Weight Loss Medications to Patient Endocrine Society Obesity Guidelines | NDEI
Endocrine Society Obesity Guidelines Treating Type 2 Diabetes PPT | NDEI
SCALE Obesity & Prediabetes Trial Liraglutide GLP-1 Design PPT | NDEI
SCALE Trial FPG Liraglutide Vs Placebo in Obese Subjects PPT | NDEI
SCALE Obesity & Prediabetes Liraglutide Blood Pressure PPT | NDEI
SCALE Obesity & Prediabetes Trial Liraglutide Hypoglycemia PPT | NDEI
Weight Loss With Liraglutide 3 mg Obese With Prediabetes SCALE ENDO2015 | NDEI
Safety & Efficacy of Lorcaserin + Phentermine Among Overweight or Obese Subjects
AACE 2015 Diabetes Guidelines Overweight/Obesity Treatment Algorithm | NDEI
Diabetes Medications & Weight AHA ADA CVD Prevention Guidelines | NDEI
Type 2 Diabetes Screening US Preventive Type 2 Diabetes Guidelines | NDEI
Type 2 Diabetes Risk Factors US Preventive Services Guidelines | NDEI
Blood Glucose Values Indicating Prediabetes or Type 2 Diabetes
Type 2 Diabetes Risk Factors Screening US Preventive Guidelines | NDEI
Type 2 Diabetes Diagnostic Criteria US Preventive Guidelines | NDEI
Screening for Type 2 Diabetes & Prediabetes in Asymptomatic Individuals
Treatment for Overweight & Obesity in Type 2 Diabetes ADA Guidelines | NDEI
Statin Therapy in Type 2 Diabetes ADA Guidelines 2016 | NDEI PPT
Statin Therapy Recommendations for Type 2 Diabetes ADA Guidelines | NDEI
Type 2 Diabetes & Prediabetes Screening ADA Guidelines | NDEI PPT
NLA Cholesterol Guidelines Metabolic Syndrome Criteria | CCMD
NLA Cholesterol Guidelines Lifestyle Therapy ASCVD Risk PPT | CCMD